Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$283.78 USD

283.78
2,379,369

-8.57 (-2.93%)

Updated Aug 6, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands

by Zacks Equity Research

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.

Zacks Equity Research

ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.

Zacks Equity Research

Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status

by Zacks Equity Research

Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.

Zacks Equity Research

Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up

by Zacks Equity Research

Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.

Zacks Equity Research

Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y

by Zacks Equity Research

Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.

Zacks Equity Research

Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.

Zacks Equity Research

Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down

by Zacks Equity Research

Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.

Zacks Equity Research

Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEV

Zacks Equity Research

Here's Why You Should Retain Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) on continued geographic expansion.

Zacks Equity Research

Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?

by Zacks Equity Research

Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.

Zacks Equity Research

Avanos (AVNS) Q4 Earnings Lag Estimates, Margins Contract

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall fourth-quarter results reflect soft performances.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Surpass, Margins Down

by Zacks Equity Research

Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.

Zacks Equity Research

Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up

by Zacks Equity Research

Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.

Zacks Equity Research

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.

Zacks Equity Research

Thermo Fisher (TMO) Introduces Dionex Inuvion IC system

by Zacks Equity Research

Thermo Fisher's (TMO) Dionex Inuvion system helps labs operate more effectively by providing simple, adjustable workflows and a small footprint.

Zacks Equity Research

IDEXX (IDXX) Unveils Pet Owner Engagement Software Solution

by Zacks Equity Research

IDEXX's (IDXX) Vello software is an intuitive solution designed specifically for practice management software that enables practitioners to interact with pet owners before and after visits.

Zacks Equity Research

PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down

by Zacks Equity Research

PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.

Zacks Equity Research

AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall fourth-quarter performance.

Zacks Equity Research

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)

by Zacks Equity Research

ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.

Zacks Equity Research

Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down

by Zacks Equity Research

Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.

Zacks Equity Research

Labcorp (LH) Q4 Earnings and Revenues Beat, Margins Fall

by Zacks Equity Research

Strength in Diagnostics Laboratories and Biopharma Laboratory Services businesses contributes to Labcorp's (LH) Q4 performance.

Zacks Equity Research

Here's Why You Should Retain IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) growth in CAG business and strong global performance

Zacks Equity Research

Avantor (AVTR) Q4 Earnings & Revenues Top Estimates, Margins Down

by Zacks Equity Research

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft fourth-quarter performance.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.